Early Market Siren: ZyVersa Therapeutics (ZVSA) is On Fire This Morning

Just Announced! ZyVersa Therapeutics (Nasdaq: ZVSA) Is Our Next  Potential Breakout Idea! And Here’s Why… Low Float: (ZVSA) has a float under 1.1 Mln shares, with past moves like an approx 85% in 24 hours. Healthcare Event: CEO Stephen C. Glover will present at JP Morgan’s 43rd Annual Healthcare Conference next week. Inflammatory Treatment: IC 100 targets ASC to control 12+ inflammasomes, addressing obesity in a $100B+ market. Renal Breakthrough: VAR 200 targets kidney damage and is advancing toward a Phase 2a trial in a $23.8B market. Proven Leadership: Backed by top scientists and 115+ years of expertise, (ZVSA) is primed for major progress. Keeping Reading To Get Up To Speed With ZyVersa Therapeutics (ZVSA)... January 10, 2025 Dear Reader, After Wednesday’s profile moved approximately 156% ahead of the opening bell, we’re turning our attention to ZyVersa Therapeutics (Nasdaq: ZVSA)—a company with some unique attributes. Here’s what stands out: (ZVSA) has an extremely low float, less than 1.1 Mln shares, according to Yahoo.  This low float can lead to significant movement when demand shifts or catalysts come into play. For example, between November 4 and 5, 2024, (ZVSA) moved approximately 85% in just 24 hours.  Keep reading to see why this is a story worth keeping on your radar. And here’s where things get even more interesting.  Next week, Stephen C. Glover, ZyVersa’s Co-Founder, Chairman, CEO, and President, is expected to be rubbing shoulders with the biggest names in healthcare at JP Morgan’s 43rd Annual Healthcare Conference in San Francisco (January 13–16, 2025).  With two proprietary product platforms developed by leading scientists at the University of Miami Miller School of Medicine, ZyVersa Therapeutics (Nasdaq: ZVSA) is setting the stage for breakthroughs in inflammatory and renal diseases—markets valued at $150B and $15B globally, respectively. Keep reading to see why ZyVersa Therapeutics (Nasdaq: ZVSA) is topping our watchlist this morning.  ZyVersa Therapeutics (Nasdaq: ZVSA)'s inflammatory ASC inhibitor, IC 100, is redefining how we treat inflammatory diseases. Unlike NLRP3 inhibitors that target a single inflammasome, IC 100 takes a broader approach by targeting ASC, a key component of multiple inflammasome pathways.  This groundbreaking mechanism allows IC 100 to inhibit 12 or more inflammasomes, offering superior control of inflammation for diseases where multiple inflammasomes are activated. IC 100 works on two levels: Prevention – It inhibits inflammasome formation and the initiation of inflammatory cascades. Propagation Control – By blocking intra- and extracellular ASC specks, it prevents systemic spread of inflammation, which often leads to comorbidities. With its lead indication targeting obesity and related metabolic complications, IC 100 positions ZyVersa as a frontrunner in a global market projected to reach over $100B by 2030.  The potential for IC 100 to expand into a broad range of CNS and peripheral inflammatory diseases further amplifies its market appeal. Revolutionizing Renal Care: VAR 200 ZyVersa Therapeutics (Nasdaq: ZVSA) is also making strides in renal diseases with VAR 200, a Cholesterol Efflux Mediator™ that clears excess cholesterol and lipids from damaged kidneys.  With FDA clearance for a Phase 2a trial in diabetic kidney disease, VAR 200 is addressing a major gap in a therapeutic area with no approved treatments targeting renal lipotoxicity. Backed by a strong intellectual property portfolio, VAR 200 holds the potential for orphan exclusivity and Priority Review Vouchers, making it a valuable addition to the $23.8B chronic kidney disease market projected by 2032. Why ZyVersa Therapeutics (Nasdaq: ZVSA) Stands Out What sets ZyVersa apart is its foundation of scientific excellence, built on decades of research and executed by a leadership team with over 115 years of combined experience in dr-ug development and commercialization.  Their dual focus on renal and inflammatory diseases uniquely positions them in two high-growth areas, offering multiple value inflection points in the near term. ZyVersa’s innovative approach, coupled with its commitment to addressing unmet medical needs, is already turning heads. The company’s combination of scientific rigor, strategic foresight, and strong market potential positions it as a potential game-changer in the biopharma space. The Bottom Line ZyVersa Therapeutics (Nasdaq: ZVSA) is not just a biotech company—it’s a catalyst for change in how we tackle complex diseases.  With a powerful pipeline, unmatched scientific innovation, and a clear vision for addressing global healthcare challenges, ZyVersa is a name to watch in 2025 and beyond. 5 Reasons Why ZyVersa Therapeutics (Nasdaq: ZVSA) is Topping Our Watchlist This Morning… 1. Low Float: ZyVersa Therapeutics (ZVSA) has a float of less than 1.1 Mln shares, creating the potential for significant movement, as seen with its 85% jump in just 24 hours last November. 2. Upcoming Healthcare Event: (ZVSA)’s CEO will attend JP Morgan’s 43rd Annual Healthcare Conference next week, a premier platform for showcasing innovations to top industry leaders. 3. Inflammatory Innovation: IC 100 targets ASC to control 12+ inflammasomes, positioning (ZVSA) to address obesity and metabolic complications in a market projected to exceed $100B by 2030. 4. Renal Health Breakthrough: VAR 200, a Cholesterol Efflux Mediator™, is tackling renal lipotoxicity and advancing toward a Phase 2a trial in a $23.8B kidney disease market. 5. Experienced Leadership: Backed by research from top scientists and a leadership team with 115+ years of expertise, (ZVSA) is strategically positioned to drive progress in high-growth markets. ZyVersa Therapeutics (Nasdaq: ZVSA) stands out with its exceptionally low float, groundbreaking innovations in inflammatory and renal health, and a leadership team ready to take center stage at one of healthcare’s most influential events next week.  With potential catalysts like these, this is a name worth putting on your radar before this morning's opening bell rings. Keep an eye out for my next update.  I’ll check back in with you shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends Click to connect no-cost SMS (takes less than 20 seconds) StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  TD Media LLC has not been compensated for the January 9th and 10th, 2025's profile on (ZVSA:US). Neither TD Media LLC or its member own shares of (ZVSA:US).

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice